Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898078 · ClinicalTrials.gov registry record · Phase 1
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
A Phase 1 study of Lymphoma and Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT01898078 is a Phase 1 study of Lymphoma and Advanced Solid Tumors that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 26 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01898078, a Phase 1 study of Lymphoma and Advanced Solid Tumors, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
Conditions Studied
Interventions
- DRUG Alisertib
Study Locations (3)
New York
- - The Bronx
Tennessee
- - Nashville
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-07-16 |
| Est. Completion | 2017-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898078
The ClinicalTrials.gov registry entry for NCT01898078 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Alisertib is the first listed.
NCT01898078 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT01898078 about?
NCT01898078 is a clinical study titled "Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas". The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
What is the current status of trial NCT01898078?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-07-16. Estimated completion is 2017-01-24.
What conditions does trial NCT01898078 study?
This clinical trial studies the following conditions: Lymphoma, Advanced Solid Tumors.
What interventions are being tested in trial NCT01898078?
The interventions under investigation include: Alisertib (DRUG).
Who is sponsoring clinical trial NCT01898078?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01898078 being conducted?
This trial has 3 study locations across New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.